Patient Highlights from the 2024 ASCO Conference

Watch RECORDING here https://youtu.be/P6qQcCwPIcQ

SLIDES available at https://drive.google.com/file/d/18Yr5hDn8-OjmtSDUvtZilyA2KK8uyfuR/view?usp=sharing

Highlights of the top prostate cancer papers from the recent ASCO annual conference were presented by AnCan moderators in a special 75-minute session preceding the 7/1/2024 High Risk / Recurrent / Advanced prostate cancer meeting. Moderators Rick Davis, John Antonucci, Len Sierra, and Ben Nathanson spoke, followed by a 30-minute audience Q&A.

Topics we covered:

* Sequence your tumor before Pluvicto

* More tough news if you’ve got the bad mutations…

* With a BRCA mutatoin, get that PARP-I quickly!

* Readily available solution to hot flashes if you’re on abi

* State-of-the-art personalized medicine and imaging

* Cushioning the blows of ADT

* A flop for metformin

* Who should get treatment holidays?

* Is alpha radiation the top dog?

* Pressing AR’s self-destruct

* An angle on neuroendocrine

* Predicting winners at immunotherapy

* Who’ll connect at BAT?

* Doublet faceoff: ADT+ chemo vs ADT+ARPI

* In triplet trials, who really needed chemo?

* Ranking PARP inhibitors for bone-marrow complications

* When PSA and PSMA go different ways

* Who’s expressing PSMA?

* Could CD46 be a better PSMA?

* Niche for precision medicine: fused genes

* AI keeps advancing

* An OS oracle from UCSF

* An OS oracle from ArteraAI

* Taking on oligomets

* Decipher without the sequencing